Periconceptional GLP-1 receptor agonist exposure and obstetric outcomes: a Danish nationwide cohort study - PubMed
2 hours ago
- #diabetes
- #preterm birth
- #GLP-1 receptor agonist
- Periconceptional GLP-1 receptor agonist exposure was associated with increased preterm birth risk in women using it for diabetes treatment (liraglutide aOR 1.70, semaglutide aOR 1.84).
- No increased preterm birth risk was observed in women using GLP-1 receptor agonists for weight management without pre-existing diabetes.
- The study suggests that underlying diabetes, rather than the medication itself, may be the causal factor for increased preterm birth risk.
- The study analyzed 756,636 singleton pregnancies in Denmark from 2009 to 2023, with 529 pregnancies having periconceptional GLP-1 receptor agonist exposure.
- Limitations include potential misclassification, lack of medication compliance data, and inability to control for unmeasured confounders.
- Funding sources included the Novo Nordisk Foundation, AP Moller Foundation, NordForsk, and others.
- Several authors disclosed financial ties to pharmaceutical companies, including Novo Nordisk, AstraZeneca, and Bayer.